In analyses restricted to T2D populations, GLP-1 receptor agonists (GLP-1RAs) showed consistent trends toward reduced risks across all seven respiratory outcomes compared with placebo; however, none reached statistical significance (all p > 0.05), and confidence intervals were wide. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.